Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ)
CNY33.29
+2.14 (+6.87%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Information Industry Park 523325
Dongguan, CN
Dongguan, CN
CEO
Yong Hong Chen
Website
zspcl.com
IPO
2009-12-11
ISIN CNE100000HW4
Description
Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the entire lifecycle of drug development, from research and development to manufacturing and commercialization. Its product portfolio encompasses both traditional Chinese medicines (TCM) and modern chemical pharmaceuticals. The company's robust research and development initiatives are directed towards creating solutions for a wide array of health conditions, specifically targeting ophthalmological, cardiovascular, cerebrovascular, respiratory, digestive, diabetic, oncological, and age-related degenerative diseases. Established in 1979, the company maintains its primary operations from its headquarters in Dongguan, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY33.29
+2.14 (+6.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
44M
Beta
0.60
Float Shares
752.26M
Free Float %
88.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.83% | -3.15% | +18.77% | +15.20% | -7.66% | +15.02% | +75.34% | +30.48% | +143.64% | +95.96% | +117.86% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
33.29
DCF (Unlevered)
2.42
-92.7%
DCF (Levered)
1.31
-96.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
11.51
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.2% Q1'26: -1.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+191.7% ★ Q1'26: +20.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.9% Q1'26: +14.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.7% Q1'26: +18.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.5% ★ Q1'26: +11.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.6% Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.73× ★ Q1'26: 0.50× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.58B
est: 1.60B (-1.2%)
|
1.69B
est: 1.79B (-5.4%)
|
1.96B
est: 1.83B (+7.6%)
|
2.36B
est: 2.29B (+3.2%)
|
2.53B
est: 2.53B (+0.0%)
|
1.90B
est: 2.79B (-31.9%)
|
2.43B
est: 3.06B (-20.7%)
|
2.68B
est: 2.77B (-3.4%)
|
2.61B
est: 2.98B (-12.5%)
|
2.47B
est: 2.69B (-8.3%)
|
2.52B
est: 2.71B (-6.8%)
|
3.09B
3.09B – 3.09B
+13.9% YoY
|
3.41B
3.41B – 3.41B
+10.4% YoY
|
| EBITDA |
382.82M
est: 275.77M (+38.8%)
|
491.46M
est: 309.13M (+59.0%)
|
464.64M
est: 315.31M (+47.4%)
|
576.35M
est: 395.37M (+45.8%)
|
572.28M
est: 437.30M (+30.9%)
|
352.45M
est: 481.09M (-26.7%)
|
462.45M
est: 529.11M (-12.6%)
|
477.90M
est: 478.33M (-0.1%)
|
465.05M
est: 515.47M (-9.8%)
|
322.53M
est: 459.14M (-29.8%)
|
443.01M
est: 462.21M (-4.2%)
|
526.56M
526.56M – 526.56M
+13.9% YoY
|
581.35M
581.35M – 581.35M
+10.4% YoY
|
| EBIT |
319.58M
est: 205.64M (+55.4%)
|
423.34M
est: 230.52M (+83.6%)
|
395.04M
est: 235.12M (+68.0%)
|
497.99M
est: 294.82M (+68.9%)
|
473.99M
est: 326.10M (+45.4%)
|
253.77M
est: 358.75M (-29.3%)
|
368.16M
est: 394.56M (-6.7%)
|
380.45M
est: 356.69M (+6.7%)
|
346.21M
est: 384.38M (-9.9%)
|
206.95M
est: 342.87M (-39.6%)
|
320.61M
est: 345.16M (-7.1%)
|
393.22M
393.22M – 393.22M
+13.9% YoY
|
434.13M
434.13M – 434.13M
+10.4% YoY
|
| Net Income |
296.71M
est: 356.80M (-16.8%)
|
414.37M
est: 409.11M (+1.3%)
|
420.12M
est: 434.89M (-3.4%)
|
435.65M
est: 475.09M (-8.3%)
|
317.73M
est: 324.09M (-2.0%)
|
-426.61M
est: 382.26M (-211.6%)
|
277.63M
est: 448.74M (-38.1%)
|
322.05M
est: 357.33M (-9.9%)
|
263.27M
est: 357.33M (-26.3%)
|
-299.16M
est: 242.33M (-223.5%)
|
275.75M
est: 294.14M (-6.2%)
|
350.96M
350.96M – 350.96M
+19.3% YoY
|
417.81M
417.81M – 417.81M
+19.0% YoY
|
| SGA |
663.78M
est: 682.46M (-2.7%)
|
724.41M
est: 765.03M (-5.3%)
|
664.52M
est: 780.31M (-14.8%)
|
850.19M
est: 978.43M (-13.1%)
|
977.20M
est: 1.08B (-9.7%)
|
852.17M
est: 1.19B (-28.4%)
|
1.08B
est: 1.31B (-17.3%)
|
1.17B
est: 1.18B (-1.3%)
|
1.04B
est: 1.28B (-18.1%)
|
1.00B
est: 1.12B (-10.9%)
|
1.01B
est: 1.13B (-10.5%)
|
1.29B
1.29B – 1.29B
+13.9% YoY
|
1.42B
1.42B – 1.42B
+10.4% YoY
|
| EPS |
0.41
est: 0.43 (-4.5%)
|
0.55
est: 0.49 (+11.7%)
|
0.52
est: 0.52 (-0.6%)
|
0.54
est: 0.57 (-5.5%)
|
0.40
est: 0.39 (+2.6%)
|
-0.53
est: 0.46 (-215.2%)
|
0.35
est: 0.54 (-35.2%)
|
0.40
est: 0.43 (-7.0%)
|
0.32
est: 0.43 (-25.6%)
|
-0.36
est: 0.29 (-224.1%)
|
0.33
est: 0.35 (-6.2%)
|
0.42
0.42 – 0.42
+19.3% YoY
|
0.50
0.50 – 0.50
+19.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
151.94M
OE per share TTM
0.18
Owner's Yield
0.87%
Maintenance CapEx ratio
51.20%
Maint CapEx / Avg PPE
26.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 19 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 1.36M | 0.07% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 780.2K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 256.0K | 0.39% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 53.4K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 23.7K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.64M | 0.06% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 145.4K | 0.29% |
| 8 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 8.8K | 0.44% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 131.9K | 0.28% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 42.1K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
180.6K
Shares Outstanding
849.93M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun Hua Long | Vice President, Chief Financial Officer, Financial Director & Director | — | female |
| Rikang Luo | Vice President | — | male |
| Shuang Liu | Vice President | — | male |
| Wei Yang | Board Secretary | — | male |
| Yong Hong Chen | Chairman & President | — | male |
| Yuchong Zhang | Vice Chairman & Senior Vice President | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002317.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
